EUVIMEDEUVIMED entdecken
Crossref

Novel quinazoline–chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies

Feyzi Sinan Tokalı, Halil Şenol, Hande İpek Yetke, Ebru Hacıosmanoğlu-Aldoğan

Archiv der Pharmazie · 2023-11 · 356 (11)

DOI: 10.1002/ardp.202300423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 21.09.2023. Verfasst von Feyzi Sinan Tokalı und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Türkiye. Hauptthemen laut MEDLINE: Benzopyrans, Antineoplastic Agents. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, new quinazoline–chromene hybrid compounds were synthesized. The cytotoxic effects on cell viability of the hybrid compounds were tested against A549 human lung adenocarcinoma and BEAS‐2B healthy bronchial epithelial cell lines in vitro. In addition, the ability of the active compounds to inhibit cell migration was tested. Molecular docking studies were performed to evaluate the ligand–protein interactions, and molecular dynamics simulations were performed to determine the interactions and stability of ligand–protein complexes. In silico absorption, distribution, metabolism, and excretion (ADME) studies were conducted to estimate the drug‐likeness of the compounds. Compounds 4 (IC 50 = 51.2 µM) and 5 (IC 50 = 44.2 µM) were found to be the most active agents against A549 cells. They are found to be more selective against A549 cells than the reference drug doxorubicin. They also have the ability to significantly inhibit cell migration. They have the best docking scores against epidermal growth factor receptor (EGFR) (−11.300 and −11.226 kcal/mol) and vascular endothelial growth factor receptor 2 (VEGFR2) (−10.987 and −11.247 kcal/mol), respectively. In MD simulations, compounds 4 and 5 have strong hydrogen bond interactions above 80% of simulation times and showed a low ligand root mean square deviation (RMSD) around 2 Å. According to the ADME analysis, compounds 4 and 5 exhibit excellent drug‐likeness and pharmacokinetic characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzopyransAntineoplastic AgentsHumansMolecular Docking SimulationStructure-Activity RelationshipQuinazolinesLigandsVascular Endothelial Growth Factor ADrug Screening Assays, AntitumorMolecular Dynamics SimulationMolecular StructureCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

chromenelung cancermolecular dockingmolecular dynamicsquniazoline

Substanzen

BenzopyransQuinazolinesLigandsVascular Endothelial Growth Factor AAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.
  • Department of Biophysics, Faculty of Medicine, Bezmialem Vakif University, Fatih, Istanbul, Türkiye.

Förderung

  • None

Zitieren

APA

Tokalı, F. S., Şenol, H., Yetke, H. İ., & Hacıosmanoğlu-Aldoğan, E. (2023). Novel quinazoline–chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies. Archiv der Pharmazie, 356(11). https://doi.org/10.1002/ardp.202300423

Vancouver

Tokalı FS, Şenol H, Yetke Hİ, Hacıosmanoğlu-Aldoğan E. Novel quinazoline–chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies. Archiv der Pharmazie. 2023;356(11). doi:10.1002/ardp.202300423

BibTeX
@article{Tokal2023,
  author = {Tokalı, Feyzi Sinan and Şenol, Halil and Yetke, Hande İpek and Hacıosmanoğlu-Aldoğan, Ebru},
  title = {Novel quinazoline–chromene hybrids as anticancer agents: Synthesis, biological activity, molecular docking, dynamics and ADME studies},
  journal = {Archiv der Pharmazie},
  year = {2023},
  volume = {356},
  number = {11},
  doi = {10.1002/ardp.202300423}
}
Kostenlos starten →